Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Doxorubicin by Shanghai Affinity Biopharmaceutical for Lung Adenocarcinoma: Likelihood of Approval
Doxorubicin is under clinical development by Shanghai Affinity Biopharmaceutical and currently in Phase III for Lung Adenocarcinoma. According to GlobalData,...
Doxorubicin by Shanghai Affinity Biopharmaceutical for Gastric Cancer: Likelihood of Approval
Doxorubicin is under clinical development by Shanghai Affinity Biopharmaceutical and currently in Phase II for Gastric Cancer. According to GlobalData,...
Doxorubicin by Shanghai Affinity Biopharmaceutical for Ovarian Cancer: Likelihood of Approval
Doxorubicin is under clinical development by Shanghai Affinity Biopharmaceutical and currently in Phase II for Ovarian Cancer. According to GlobalData,...
Doxorubicin by Shanghai Affinity Biopharmaceutical for Breast Cancer: Likelihood of Approval
Doxorubicin is under clinical development by Shanghai Affinity Biopharmaceutical and currently in Phase II for Breast Cancer. According to GlobalData,...